In absence of enough patients to correlate the risk of dissection with the phenotype and the gender, as it was done for TGBFR1 and TGFBR2 (Jondeau et al., 2016), the follow‐up and treatment of aortic manifestations in SRD is the same as in MFS. This evidence concerns the gene TGFBR2 and dopa-responsive dystonia due to sepiapterin reductase deficiency.